These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

528 related items for PubMed ID: 19808839

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice.
    Yano S, Zhang H, Hanibuchi M, Miki T, Goto H, Uehara H, Sone S.
    Clin Cancer Res; 2003 Nov 01; 9(14):5380-5. PubMed ID: 14614023
    [Abstract] [Full Text] [Related]

  • 6. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.
    Lipton A, Colombo-Berra A, Bukowski RM, Rosen L, Zheng M, Urbanowitz G.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 2):6397S-403S. PubMed ID: 15448038
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence.
    Smith MR.
    Cancer Treat Rev; 2005 Sep 15; 31 Suppl 3():19-25. PubMed ID: 16229955
    [Abstract] [Full Text] [Related]

  • 13. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).
    Facchini G, Caraglia M, Santini D, Nasti G, Ottaiano A, Striano S, Maiolino P, Ruberto M, Fiore F, Tonini G, Budillon A, Iaffaioli RV, Zeppetella GL.
    J Exp Clin Cancer Res; 2007 Sep 15; 26(3):307-12. PubMed ID: 17987788
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Optimal management of metastatic bone disease.
    Major P.
    Eur J Oncol Nurs; 2007 Sep 15; 11 Suppl 2():S32-7. PubMed ID: 17804294
    [Abstract] [Full Text] [Related]

  • 16. The potential application of zoledronic acid as anticancer therapy in patients with non-small-cell lung cancer.
    Mahtani R, Khan R, Jahanzeb M.
    Clin Lung Cancer; 2011 Jan 15; 12(1):26-32. PubMed ID: 21273176
    [Abstract] [Full Text] [Related]

  • 17. Under usage of zoledronic acid in non-small cell lung cancer patients with metastatic bone disease--a short communication.
    Calderone R, Nimako K, Leary A, Popat S, O'Brien ME.
    Eur J Cancer; 2011 Jul 15; 47(11):1603-5. PubMed ID: 21684152
    [Abstract] [Full Text] [Related]

  • 18. Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
    Smidt-Hansen T, Folkmar TB, Fode K, Agerbaek M, Donskov F.
    J Oral Maxillofac Surg; 2013 Sep 15; 71(9):1532-40. PubMed ID: 23642545
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.